Skip to content
OpenCapital
Get started

Fate Therapeutics FATE Q4 2024 Annual earnings

Reported March 5, 2025 · Before market open

Revenue$1.9MBeat by $291.3KDiluted EPS-$0.31Beat by $0.13
Revenue estimate$1.6M
EPS estimate-$0.44

Next report

Aug 11, 2026 (In 4 weeks)
Revenue estimate$1.4M
EPS estimate-$0.28

Versus estimates

Revenue

Q1 2026$1.3MMiss by $192.9KQ4 2025$1.4MBeat by $32.4KQ3 2025$1.7MBeat by $542.9KQ2 2025$1.9MBeat by $758.1KQ1 2025$1.6MBeat by $444.6K
Q4 2024$1.9MBeat by $291.3K

Diluted EPS

Q1 2026-$0.26Beat by $0.03Q4 2025-$0.27In lineQ3 2025-$0.27Beat by $0.02Q2 2025-$0.29Beat by $0.06Q1 2025-$0.32Beat by $0.07
Q4 2024-$0.31Beat by $0.13

Ask the moment Fate Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Fate Therapeutics report Q4 2024 earnings?
Fate Therapeutics (FATE) reported Q4 2024 earnings on March 5, 2025 before market open.
What were Fate Therapeutics's Q4 2024 revenue and EPS?
Fate Therapeutics reported revenue of $1.9M and diluted EPS of $-0.31 for Q4 2024.
Did Fate Therapeutics beat estimates in Q4 2024?
Revenue beat the consensus estimate of $1.6M by $291.3K. EPS beat the consensus estimate of $-0.44 by $0.13.
Where can I find Fate Therapeutics's Q4 2024 SEC filings?
You can read the 10-K periodic report (0000950170-25-033510) directly on SEC EDGAR. The filing index links above go to sec.gov.